ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Gene/Gene Panel: RYR2
Context: Adult
Date
Status
Outcomes-Interventions
Notes
2022/02/09
Released
2.0.1
Sudden cardiac death (GroupA)
Avoidance of intense exercise (GroupA) 10CN
Antiarrhythmic therapy with beta-blockers and consideration for more intensive therapies as indicated (GroupA) 10CA
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
RYR2 0011484 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
Strong Actionability
Strong Actionability
CASQ2 0012762 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
Strong Actionability
Strong Actionability
TRDN 0014191 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
Strong Actionability
Strong Actionability
CALM1 0013966 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
Strong Actionability
Moderate Actionability
CALM2 0017990 LONG QT SYNDROME 15; LQT15
Strong Actionability
Moderate Actionability
CALM3 0032915 LONG QT SYNDROME 16; LQT16
Strong Actionability
Moderate Actionability
TECRL 0013529 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
Strong Actionability
Strong Actionability
2022/02/09
Released (Under revision)
2.0.0
Sudden cardiac death (GroupA)
Avoidance of intense exercise (GroupA) 10CN
Antiarrhythmic therapy with beta-blockers and consideration for more intensive therapies as indicated (GroupA) 10CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
RYR2 0011484 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
Strong Actionability
Strong Actionability
CASQ2 0012762 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
Strong Actionability
Strong Actionability
TRDN 0014191 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
Strong Actionability
Strong Actionability
CALM1 0013966 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
Strong Actionability
Moderate Actionability
CALM2 0017990 LONG QT SYNDROME 15; LQT15
Strong Actionability
Moderate Actionability
CALM3 0032915 LONG QT SYNDROME 16; LQT16
Strong Actionability
Moderate Actionability
TECRL 0013529 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
Strong Actionability
Strong Actionability
2021/09/20
Released
2.0.0
Sudden cardiac death (GroupA)
Avoidance of intense exercise (GroupA) 10CN
Antiarrhythmic therapy with beta-blockers and consideration for more intensive therapies as indicated (GroupA) 10CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
RYR2 0011484 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
Strong Actionability
Strong Actionability
CASQ2 0012762 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
Strong Actionability
Strong Actionability
TRDN 0014191 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
Strong Actionability
Strong Actionability
CALM1 0013966 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
Strong Actionability
Moderate Actionability
CALM2 0017990 LONG QT SYNDROME 15; LQT15
Strong Actionability
Moderate Actionability
CALM3 0032915 LONG QT SYNDROME 16; LQT16
Strong Actionability
Moderate Actionability
TECRL 0013529 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
Strong Actionability
Strong Actionability
2021/08/04
Released (Under revision)
1.2.1
Sudden cardiac death (GroupA)
Beta blockers (GroupA) 10NB
MONDO IDs added, scoring groups unadjusted.
2020/12/23
Released
1.2.1
Sudden cardiac death (GroupA)
Beta blockers (GroupA) 10NB
MONDO IDs added, scoring groups unadjusted.
2020/02/18
Released (Under revision)
1.2.0
Sudden cardiac death (GroupA)
Beta blockers (GroupA) 10NB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.2.0
Sudden cardiac death (GroupA)
Beta blockers (GroupA) 10NB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.1.0
Sudden cardiac death
Beta blockers 10NB
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.0.3
Sudden cardiac death
Beta blockers 10NB
Internal system migration related to score text replacement from E to N
2018/01/11
Released
1.0.2
Sudden cardiac death
Beta blockers 10EB
2017/10/23
Released
1.0.1
Sudden cardiac death
Beta blockers 10EB
¤ Powered by BCM's Genboree.